A Safety Study of XL019 in Adults With Myelofibrosis

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00522574
Study type	Interventional
Source	Exelixis
Contact
Status	Terminated
Phase	Phase 1
Start date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02916979` - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG	Phase 1
Not yet recruiting	`NCT06345495` - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly	Phase 2
Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
Completed	`NCT02784496` - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis	Phase 2
Completed	`NCT00069680` - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting	`NCT04097821` - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients	Phase 1/Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting	`NCT06397313` - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis	Phase 2
Not yet recruiting	`NCT06024915` - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets	Phase 1
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Completed	`NCT02910258` - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed	`NCT00997386` - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States	Phase 2
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00666549` - Research Tissue Bank
Terminated	`NCT00522990` - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias	Phase 1/Phase 2
Terminated	`NCT00393380` - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor	Phase 2
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Active, not recruiting	`NCT03952039` - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	Phase 3
Not yet recruiting	`NCT04709458` - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis	Phase 1